A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...
MedPage Today on MSN
Myeloma combo with 'unprecedented' effect wins FDA approval
In second- or later-line setting, combination cut risk of disease progression or death by ...
BioAtla has engaged Tungsten Advisors as the Company’s exclusive strategic financial advisor. There can be no assurance that this process will result in any such transaction. BioAtla does not intend ...
过去两年，细胞治疗赛道正经历一场隐秘而猛烈的底层重构。礼来收购Orna、艾伯维拿下Capstan、BMS也躬身入局……跨国巨头们超60亿美元的密集扫货，释放出一个极其明确的信号：In vivo CAR-T已处于产业化爆发的前夕。 传统Ex vivo CAR-T动辄数十万美元的定价与繁杂的制备周期，使其深陷个性化定制的商业泥沼，而In vivo CAR-T正以颠覆者的姿态，将细胞疗法拉回现代制药的规 ...
Healsan技术加持，让科研和SCI论文成为临床工作的副产品。CAR-T细胞疗法在血液肿瘤领域及自身免疫性疾病方面都已改变治疗格局，但在实体瘤中始终未能取得类似突破。其核心瓶颈并不完全来自肿瘤微环境或T细胞衰竭，而是一个更基础的问题--缺乏真正具有 ...
引言嵌合抗原受体T细胞（Chimeric Antigen Receptor T cells, CAR-T）疗法在血液恶性肿瘤（Hematological Malignancies）中取得了革命性的突破，但在实体瘤（Solid ...
Johnson & Johnson , a worldwide leader in multiple myeloma therapies, today announced that the U.S. Food and Drug ...
自2017年全球首个CAR-T疗法获批以来，这项技术在血液肿瘤领域取得了显著的成果，但在实体瘤领域，它却始终未能复制同样的成功。肿瘤微环境的免疫抑制和物理屏障，以及更关键的抗原表达异质性与抗原逃逸问题，是实体瘤CAR-T疗法面临的核心挑战。
BioAtla, Inc. (NASDAQ: BCAB or the "Company"), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...
Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare Conference. For next session or first session of the day, actually, very ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果